Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fred Saad

Showing results (821-830 of 993) with videos related to

Pageof 100
Sort By:
Urologic Oncology|September 7, 2025
Inflammatory bowel disease vs. adverse in-hospital outcomes after radical prostatectomyCalogero Catanzaro, Natali Rodriguez Peñaranda, Andrea Marmiroli, et al.
Journal of Surgical Oncology|June 13, 2025
Cancer-Specific Survival of Trimodal Therapy Versus Radical Cystectomy in T2N0M0 Non-Urothelial Bladder CancerMattia Longoni, Andrea Marmiroli, Fabian Falkenbach, et al.
Journal of Surgical Oncology|July 12, 2026
Open Conversion at Robotic Adrenalectomy: Rates and PredictorsAndrea Marmiroli, Mattia Longoni, Quynh Chi Le, et al.
BJU International|December 12, 2024
Survival after trimodal therapy in octogenarians with organ-confined urothelial bladder cancerMattia Longoni, Francesco Di Bello, Natali Rodriguez Peñaranda, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|October 29, 2024
Practice patterns and predictors of treatment intensification in patients with metastatic castration-sensitive prostate cancerGeoffrey T Gotto, Steven M Yip, Bobby Shayegan, et al.
Surgical Oncology|November 4, 2025
Sarcomatoid dedifferentiation as a predictor of overall mortality in surgically treated metastatic renal cell carcinomaReha-Baris Incesu, Lukas Scheipner, Simone Morra, et al.
The Lancet. Oncology|October 3, 2021
Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 studyFred Saad, Eleni Efstathiou, Gerhardt Attard, et al.
The Lancet. Oncology|September 23, 2014
Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trialCora N Sternberg, Daniel Castellano, Gedske Daugaard, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|May 2, 2026
Extent of Pelvic Lymph Node Dissection at Partial Cystectomy: Effect on Cancer-Specific MortalityMattia Longoni, Andrea Marmiroli, Fabian Falkenbach, et al.
JCO Precision Oncology|May 11, 2026
Detection of Homologous Recombination Repair Gene Mutations by Tumor Tissue and Circulating Tumor DNA Testing in Prostate Cancer in the Phase III PROpel TrialAndrew J Armstrong, Fred Saad, Mototsugu Oya, et al.
Pageof 100

Showing results (821-830 of 993) with videos related to

Sort By:
Pageof 100
Urologic Oncology|September 7, 2025
Inflammatory bowel disease vs. adverse in-hospital outcomes after radical prostatectomyCalogero Catanzaro, Natali Rodriguez Peñaranda, Andrea Marmiroli, et al.
Journal of Surgical Oncology|June 13, 2025
Cancer-Specific Survival of Trimodal Therapy Versus Radical Cystectomy in T2N0M0 Non-Urothelial Bladder CancerMattia Longoni, Andrea Marmiroli, Fabian Falkenbach, et al.
Journal of Surgical Oncology|July 12, 2026
Open Conversion at Robotic Adrenalectomy: Rates and PredictorsAndrea Marmiroli, Mattia Longoni, Quynh Chi Le, et al.
BJU International|December 12, 2024
Survival after trimodal therapy in octogenarians with organ-confined urothelial bladder cancerMattia Longoni, Francesco Di Bello, Natali Rodriguez Peñaranda, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|October 29, 2024
Practice patterns and predictors of treatment intensification in patients with metastatic castration-sensitive prostate cancerGeoffrey T Gotto, Steven M Yip, Bobby Shayegan, et al.
Surgical Oncology|November 4, 2025
Sarcomatoid dedifferentiation as a predictor of overall mortality in surgically treated metastatic renal cell carcinomaReha-Baris Incesu, Lukas Scheipner, Simone Morra, et al.
The Lancet. Oncology|October 3, 2021
Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 studyFred Saad, Eleni Efstathiou, Gerhardt Attard, et al.
The Lancet. Oncology|September 23, 2014
Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trialCora N Sternberg, Daniel Castellano, Gedske Daugaard, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|May 2, 2026
Extent of Pelvic Lymph Node Dissection at Partial Cystectomy: Effect on Cancer-Specific MortalityMattia Longoni, Andrea Marmiroli, Fabian Falkenbach, et al.
JCO Precision Oncology|May 11, 2026
Detection of Homologous Recombination Repair Gene Mutations by Tumor Tissue and Circulating Tumor DNA Testing in Prostate Cancer in the Phase III PROpel TrialAndrew J Armstrong, Fred Saad, Mototsugu Oya, et al.
Pageof 100